Development of a quality control panel based on patient-derived immortalized B-Lymphoblastoid cell lines for thalassemia genotyping Authors: Huiling Zhang, Liqiao Han, Yingyi Feng, Longqiang Yang, Yuxiang Qiu, Cheng Zhang, Tingting Li, Peifeng Ke, Qi Kong, Yuanyuan Liu, Chenyang Yao, Xianzhang Huang, Yi Wang Published: 2026 ABSTRACT AbstractBackgroundThalassemia diagnosis relies on precise genetic testing, which requires reliable quality control (QC) materials. Current options, such as limited clinical samples or synthetic DNA, lack both renewable supply and the ability to authentically mimic patient samples across the entire testing process. To address this gap, we developed and validated a novel panel of QC materials based on patient-derived Immortalized B-Lymphoblastoid cell lines for thalassemia genotyping.MethodsPBMCs from 12 patients with thalassemia were immortalized using an optimized EBV-transformation protocol supplemented with specific growth factors and regulators. The resulting cell lines were then prepared as QC materials by cryopreservation at a defined optimal density in a serum-free solution. We assessed the stability of these QC materials under various conditions, including freeze-thaw cycles, long-term and short-term storage, by analyzing DNA integrity via agarose gel electrophoresis, quantifying ACTB copy number using droplet digital PCR and validating reference mutant loci using gap-PCR or Sanger sequencing. Furthermore, their commutability was confirmed across five different genotyping platforms.ResultsThe optimized EBV-transformation protocol significantly outperformed the basic method, increasing the transformation efficiency to 90.0% (from 53.1%, p < 0.05) and reducing the required time to 18.8 days (from 28.8 days, p < 0.05). Following resuscitation, the cryopreserved cell lines maintained stable morphology and proliferative capacity for at least 21 days in culture. Comprehensive validation confirmed the QC materials' stability, demonstrated by intact genomic DNA fragment, stable reference loci and consistent reference genes copy numbers, across various storage conditions, as well as their commutability, yielding uniform genotyping results across multiple detection platforms.ConclusionWe have established a comprehensive and stable QC panel for thalassemia genotyping that serves as a standardized resource for quality assurance, with the potential to be extended as a model for other genetic disorders.Keywords: Thalassemia, Quality control materials, Immortalized cell lines, Genotyping Introduction Thalassemia is an inherited hemoglobin disorder characterized by deficient hemoglobin synthesis, resulting in chronic anemia and exhibiting high prevalence in populations across the Mediterranean, Asia, and Africa [1]. Conventional clinical management relies on regular blood transfusions and iron chelation therapy, which are largely palliative and associated with significant complications, including iron overload [2]. Genetic screening plays a critical role in facilitating accurate diagnosis, enabling informed reproductive choices, and guiding personalized treatment strategies [3]. Owing to the heterogeneity of mutations in the globin genes, a variety of detection platforms such as PCR, hybridization-based assays, and next-generation sequencing are routinely employed. The use of high-quality quality control (QC) materials is therefore essential to ensure analytical accuracy and methodological interoperability [4], [5]. Current QC materials for thalassemia genetic testing mainly comprise two types: synthetic reference materials (e.g., genomic DNA and plasmid DNA) and well-characterized clinical specimens [6], [7]. The former allows for large-scale production and exhibits favorable stability; however, they are typically introduced after nucleic acid extraction and thus fail to monitor pre-analytical procedures, while also being susceptible to degradation and contamination. In contrast, clinical samples provide end-to-end process quality control by mirroring the entire testing workflow from sample processing to data analysis. Nevertheless, their limited availability and non-renewable nature constrain widespread application in routine quality assurance [8]. Therefore, there is a pressing need to develop novel QC materials that combine the advantages of both categories. An ideal thalassemia genetic testing material should be renewable and integrated into all phases of testing, including DNA extraction and amplification, to systematically address the limitations of existing options [9]. Immortalized cell lines offer a promising alternative that combines the biological relevance of primary clinical samples with the scalability of synthetic systems [10], [11], [12]. Established methods include Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells and CRISPR-engineered isogenic lines, both of which have been widely employed in genetic studies [13], [14], [15]. However, CRISPR-based approaches carry inherent risks, such as off-target effects and unintended genomic alterations. Meanwhile, the EBV transformation technique has been reported to exhibit variable efficiency, and detailed protocols for the construction of EBV-based vectors remain inadequately documented. These limitations underscore the need for improved immortalization strategies that ensure both high efficiency and genetic integrity. The development of such a robust methodology is critical for enhancing quality control in clinical genetic diagnostics. This study established immortalized B-lymphoblastoid cell lines from patients with thalassemia using an optimized Epstein–Barr virus (EBV) transformation protocol, which significantly improved transformation efficiency and yielded 12 cell lines carrying various thalassemia genotypes. These cell lines were used to develop a set of quality control (QC) materials that preserve native globin gene mutations and demonstrate excellent stability. Furthermore, commutability was validated across multiple genetic detection platforms, confirming their suitability for internal quality control in diverse methodological settings. The resulting QC system provides a standardized, renewable resource for enhancing accuracy in thalassemia genetic testing, supporting assay validation, laboratory proficiency testing, and ultimately promoting standardization in screening and prenatal diagnostics. Methods and materials Reagents RPMI 1640 medium was purchased from Thermo Fisher (Waltham, MA, USA). Fetal bovine serum was purchased from ExCell Bio (Suzhou, China). Serum-free cryopreservation solution was purchased from NCM Biotech (Suzhou, China). EGF, bFGF, hydrocortisone, PHA-M and cyclosporin A were purchased from MCE (New Jersey, USA). CpG ODN 2006 were purchased from Sangon Biotech (Shanghai) Co.,Ltd. (Shanghai, China). Cell line construction Immortalized human lymphocyte cell lines were established using a basic [16] or an optimized Epstein-Barr virus (EBV) transformation protocol. For optimized method, briefly, peripheral blood mononuclear cells (PBMCs) were isolated from heparinized human peripheral blood via density gradient centrifugation. The transformation was conducted using an optimized culture medium based on RPMI 1640 supplemented with 20% fetal bovine serum, 10 ng/ml epidermal growth factors (EGF) and basic fibroblast growth factors (bFGF), and regulatory components (0.5 μg/ml hydrocortisone, 2.5 μg/ml PHA-M, 1 μg/ml cyclosporin A, and 2.5 μg/ml CpG ODN 2006) to enhance B cell survival, proliferation and EBV transformation efficiency [17]. PBMCs were mixed with an equal volume of EBV suspension at a final concentration of 1 × 107 copies/ml and incubated at 37 °C with 5% CO₂ under orbital shaking at 70 rpm for 2 h. After incubation, transformation medium was added for continued culture. Half-medium changes were performed weekly. Immortalized cell clusters typically formed within 14 to 30 days, characterized by cell aggregation and rapid proliferation. Cells were cryopreserved at a density of 5 × 106 cells/ml in liquid nitrogen to establish a cell bank. The blood samples used were collected from healthy donors and patients with thalassemia in Guangdong Provincial Hospital of Chinese Medicine, with each cell line originating from an individual subject. The study received approval from the Ethics Committee of the Guangdong Provincial Hospital of Chinese Medicine (approval no. BE2022–160-01). Preparation of QC materials The immortalized cell line carrying thalassemia gene mutations was thawed and expanded in culture. Cells in the logarithmic growth phase were harvested, counted using a CAL3000 blood cell counting instrument (mindray, Shenzhen, China), and adjusted to concentrations of 0.5, 1, 2, and 4 × 106 cells/ml, concentrations that span the normal physiological range for human peripheral blood lymphocytes. The cell suspension was aliquoted into tubes (1 ml per tube), followed by centrifugation and removal of the supernatant. The resulting cell pellets were resuspended in 1 ml of serum-free cryopreservation solution [18]. All prepared control materials were stored at −80 °C for subsequent use. DNA extraction Magnetic beads and spin column were used for DNA extraction. The magnetic beads extraction method employs the DNA Extraction Kit from DAAN GENE Co., Ltd. (Guangzhou, China), and the extraction procedure follows the manufacturer's instructions. Briefly, 200 μl of the sample, 20 μl of Proteinase K, 200 μl of magnetic beads suspension and 200 μl of magnetic beads binding solution were mixed, and then incubated at 56 °C for 10 min. The magnetic beads were then collected using a magnetic separation rack, and the supernatant was removed. This was followed by two washes with washing buffer. Fifty μl of elution buffer (EB) was added to elute the genomic DNA. Spin column extraction method was performed using the FastPure Blood DNA Isolation Kit from Novogene Co., Ltd. (Guangzhou, China) according to the manufacturer's protocol. Briefly, 200 μl of sample was incubated with 20 μl proteinase K and 200 μl BCL buffer at 56 °C for 10 min. Then, 200 μl of anhydrous ethanol was added and the mixture was vortexed briefly. The resulting lysate was transferred to a spin column to promote DNA binding, after which the column was washed sequentially with 500 μl WA buffer and 700 μl WB buffer. Finally, genomic DNA was eluted with 50 μl EB buffer. The concentration and purity of DNA were assessed using a NanoDrop 2000 spectrophotometer (ThermoFisher, Waltham, MA, USA) by measuring absorbance at 260 nm (A₂₆₀) and the ratio of A₂₆₀/A₂₈₀. Stability assessment of QC materials The short-term stability, long-term stability, and freeze-thaw stability of QC materials were evaluated as previously described [19]. For the short-term stability assessment, QC materials were stored at room temperature (RT) between 20 and 25 °C for 1, 3, and 5 days, with three replicates each. After these periods, the samples were transferred to liquid nitrogen for storage. To assess long-term stability, QC materials stored at −20 °C for 3, 6, and 12 months were randomly selected, with three replicates each, and subsequently transferred to liquid nitrogen. For freeze-thaw stability assessment, QC materials underwent repeated freeze-thaw cycles between liquid nitrogen and a 37 °C water bath for 1, 3, and 5 cycles, with three replicates each. At the endpoints of the assessment periods, all samples were thawed and DNA was extracted. The stability of the QC materials was assessed through three indicators: (1) to assess amplification stability, the copy number of a reference gene (ACTB) was measured using droplet digital PCR (ddPCR), and then converted to the logarithmic value of copy number concentration per milliliter of QC material (log10 ACTB) for regression analysis; (2) to assess DNA fragment integrity, DNA fragment size was analyzed using agarose gel electrophoresis; and (3) to assess reference locus stability, multiple common mutation sites were detected using gap-PCR or Sanger sequencing. Agarose gel electrophoresis Agarose gel electrophoresis was performed to assess the genomic DNA integrity and detect products of gap-PCR. Briefly, a mixture of 9 μl genomic DNA of PCR products and 1 μl 10 × loading buffer was loaded into a 1.2% (w/v) agarose gel, along with 5 μl of DL10000 DNA marker as a molecular weight reference. Electrophoresis was carried out at a constant voltage of 100 V for 60 min using a standard electrophoresis power supply. Following electrophoresis, the gel was visualized under 302 nm UV light using a Gel-Doc XR+ gel imaging system (Bio-rad, Hercules, CA, USA). Droplet digital PCR Each reaction was set up in a total volume of 22 μl containing the following components: 11 μl of 2 × ddPCR Probe Supermix (Bio-Rad, Hercules, CA, USA); forward and reverse primers, each at 0.8 μM; probe at 0.25 μM (stock concentration 10 μM) for the ACTB gene; 0.1 Unit of BamHI restriction enzyme (NEB, Ipswich, MA, USA); 20 ng of DNA; and ddH2O was added to adjust the final volume to 22 μl. Next, water-in-oil droplets were generated using the Bio-Rad droplet generator (Hercules, CA, USA). The thermal cycling protocol included an initial denaturation at 95 °C for 10 min (1 cycle), followed by 40 cycles of 94 °C for 30 s and 60 °C for 1 min, and a final extension at 98 °C for 10 min (1 cycle). After PCR, fluorescence was measured using the Bio-Rad QX200 droplet reader (Hercules, CA, USA), and the copy number of the ACTB was analyzed using Bio-Rad QuantaSoft™ Analysis Pro software. ACTB primers sequence: 5F-CTGGAACGGTGAAGGTGACA, 3R-GTCCTCGGCCACATTGTGAA; TaqMan probe sequence: AGTCGGTTGGTTGG. Thalassemia gene detection methods Sanger sequencing Sanger sequencing was performed using the chain termination method. PCR products were purified with ExoSAP-IT to remove residual primers and unincorporated dNTPs. Sequencing reactions were carried out using the BigDye Terminator v3.1 kit (Applied Biosystems) according to the manufacturer's instructions. Each 10 μl reaction contained 2 μl of purified PCR product, 2 μl of BigDye Terminator v3.1, 1 μl of 5× sequencing buffer, 1 μl of sequencing primer (3.2 pmol/μl), and 4 μl of nuclease-free water. The cycling conditions were: 96 °C for 1 min, followed by 25 cycles of 96 °C for 10 s, 50 °C for 5 s, and 60 °C for 4 min. After amplification, sequencing products were purified by ethanol/EDTA/sodium acetate precipitation to remove unincorporated dye terminators, then denatured and separated by capillary electrophoresis on an Applied Biosystems 3500 Genetic Analyzer. Sequence data were analyzed using Sequencing Analysis Software (Applied Biosystems) and compared with reference sequences to identify mutations. Sanger sequencing can detect point mutations and small insertions/deletions but is not suitable for identifying large fragment deletions. Fluorescence-based PCR melting curve analysis Detection was performed using the Thalassemia Gene Detection Kit from Zeesan Biotech Co., Ltd. (Xiamen, China) according to the manufacturer's instructions. Twenty microliters of PCR reaction solution and 5 μl of DNA sample were mixed and transferred to the Veriti® 96-Well Thermal Cycler (ThermoFisher, Waltham, MA, USA) for amplification. Following amplification, melting curve analysis was performed using the CFX96 real-time fluorescence PCR instrument (Bio-Rad). Specific gene deletions or mutations were identified by distinguishing the melting temperature (Tm) of the DNA amplification products. PCR-flow-through hybridization The Thalassemia Gene Detection Kit from Hybribio Co., Ltd. (Guangzhou, China) was used according to the manufacturer's instructions. Briefly, 44 μl of amplification reagent and 6 μl of DNA sample were mixed and transferred to the Veriti® 96-Well Thermal Cycler for amplification. Subsequently, the amplification products were hybridized via flow-through to nylon membranes containing distinct capture probes using an automatic hybridization instrument (HB-2012 A), and results were interpreted within 1 h through chemical color development. Genotypes were determined by visually assessing the coloration of the dots and comparing them with the probe distribution schematic. Gap-PCR method The α-Thalassemia Gene Detection Kit from Yanen Biotechnology Co., Ltd. (Shenzhen, China) was used according to the manufacturer's instructions. Four microliters of DNA sample were added to 26 μl of reaction solution, mixed thoroughly, and amplification was then performed. After amplification, 5 μl of the amplification product was subjected to agarose gel electrophoresis. Nucleic acid fragments were detected using the Bio-Rad UV gel imaging system. Gene deletions were identified based on the molecular weight of the amplified fragments, with wild-type at ∼1.7 kbp, −α3.7 at ∼2.0 kbp, −α4.2 at ∼1.4 kbp, and – –SEA at ∼1.2 kbp. Due to its technical principle, gap-PCR can only detect common deletion-type α-thalassemia mutations. PCR-reverse dot hybridization method The Thalassemia Gene Detection Kit from Yanen Biotechnology Co., Ltd. (Shenzhen, China) was used according to the manufacturer's instructions. Two microliters of DNA sample were added to the reaction solution, mixed thoroughly, and amplification was performed. The PCR products were hybridized with membrane strips using the YN-H96 automatic nucleic acid molecular hybridization instrument (Yanen, Shenzhen, China). The genotype of the tested sample was determined based on the color development of the spots on the membrane strip. Genotypes were determined by visually assessing the coloration of the dots and comparing them with the probe distribution schematic. This kit is designed to only detect predefined point mutations and small indels through allele-specific probes. PCR-MALDI-TOF-MS PCR-MALDI-TOF-MS-based kits for thalassemia genotyping were from Hybribio Co., Ltd. (Guangzhou, China), with experimental procedures performed according to the manufacturer's instructions. Briefly, the process involved multiplex PCR amplification, shrimp alkaline phosphatase (SAP) treatment to remove the remained dNTP, and single-base extension (SBE) reaction using ddNTP. The products were then analyzed by MALDI-TOF MS on a MassARRAY platform. Data interpretation was carried out using Typer 4.0 software, with genotype calls based on mutant-to-wild-type peak height ratios: homozygous (> 3), heterozygous (0.5–3), or wild-type (< 0.5) [20]. Statistical analysis The Student's t-test was used to compare the data in Table 1. Statistical analysis was performed with SPSS 26.0, and statistical significance was defined as a two-tailed p value <0.05. Table 1Transformation of Lymphocytes and sample characteristics.Basic EBV transformation MethodOptimized EBV transformation MethodPNo. of individuals3230Age of participant33.7 ± 7.834.2 ± 8.3>0.05No. of successful transformed individuals1928Transformation success rate (%)53.190.0<0.05Times to successful transformation (days)28.8 ± 9.418.8 ± 5.1<0.05 Transformation of Lymphocytes and sample characteristics. Results Establishment of cell lines In the present study, we improved the EBV transformation method by adding components such as EGF and bFGF based on the basic EBV transformation method. Through experiments on multiple clinical samples, we found that compared to the basic EBV transformation method, the improved method significantly increased the transformation efficiency of human lymphocytes (90.0% vs 53.1%, p < 0.05) and shortened the time required for transformation (18.8 days vs 28.8 days, p < 0.05) (Table 1). Using the improved EBV transformation method, we successfully obtained twelve Immortalized B-Lymphoblastoid lines from patients with α-thalassemia (−−SEA/αα, −α3.7/αα, −α4.2/αα, αWSα/αα) or β-thalassemia (βCD41–42(-TTCT)/βN, βCD43(G > T)/βN, βIVS-II-654(C > T)/βN, βIVS-I-1(G > T)/βN, βCD17(A > T)/βN, βCD-28(A > G)/βN, βCAP+40–43(-AAAC)/βN, βE(79G > A)/βN). These cell lines were then cryopreserved in liquid nitrogen. To verify the viability of the cryopreserved cell lines, we thawed the frozen cells and seeded them at a density of 1 × 105 cells/ml in 6-well plates, followed by continuous culture for 21 days with passage every 3 days. Microscopic imaging revealed that three representative cell lines (−α4.2/αα, αWSα/αα and βIVS-II-654(C > T)/βN) grew in clusters with intact morphology after resuscitation (Fig. 1A). Cell counting results showed that the cell line exhibited rapid proliferation and stable passaging characteristics during the 21-day culture period post-resuscitation (Fig. 1B). Morphology and proliferation of immortalized cell lines. (A) Cell colony photos of Thal-QC-004, Thal-QC-005 and Thal-QC-008 (magnification of 100 × and 400 ×, respectively). The scale bar represents 100 μm. (B) Cell counting of the cell lines during the 21-day culture period post-resuscitation. Data are from three independent biological replicates. Error bars represent the mean ± SD (standard deviation) (n = 3). QC material stability To ensure cell integrity and prevent exogenous DNA contamination, commercial serum-free freezing medium was chosen for preparing QC materials. The optimal cell density was determined by testing a range from 0.5 × 106 to 4 × 106 cells/ml, which aligns with human peripheral blood lymphocyte counts. Evaluation of DNA extracted by magnetic bead and spin column methods confirmed that all samples (using cell line Thal-QC-005 as a representative) met the required specifications for subsequent experiments (DNA > 10 ng/μl, A260/A280 > 1.80) (Fig. 2A and B). Considering both DNA quality and production costs, a concentration of 1 × 106 cells/ml was deemed optimal for the QC materials. Performance of QC materials. (A-B) Concentration (A) and purity (B) of DNA extracted from quality control (QC) material (Thal-QC-005) (0.5, 1, 2, and 4 × 106 cells/mL). Data are from three independent biological replicates. Error bars represent the mean ± SD (n = 3). (C) Regression analysis of log10ACTB copy numbers concentration (log10ACTB) in QC material (Thal-QC-005) under different stability validation conditions. p values indicate the significance of the slopes (vs. zero, 95% CI). (D) Agarose gel electrophoresis of DNA from QC material (Thal-QC-005) under different stability validation conditions. Lane 1–4: Freeze-thaw cycles 0–5; Lane 5–8: −20 °C storage 0–12 months; Lane 9–12: room temperature (RT) 0–5 days. (E) Summary table of freeze-thaw stability assessment for key mutation sites in QC materials using gap-PCR or Sanger sequencing methods. The “√” indicates consistent results. (F) Representative results of gap-PCR assay. Lanes 1–4, sample Thal-QC-001 subjected to 0–5 freeze-thaw cycles; Lanes 5–8, sample Thal-QC-002 subjected to 0–5 freeze-thaw cycles. (G) Representative results of Sanger sequencing assay (samples Thal-QC-005, −006, −008 and −010 subjected to 0 freeze-thaw cycles). The stability of the QC products was evaluated under repeated freeze-thaw cycles, long-term storage at −20 °C, and short-term storage at room temperature (RT). ACTB gene copy numbers, DNA integrity and key mutant loci were detected using ddPCR, agarose gel electrophoresis and gap-PCR or Sanger sequencing respectively. The slopes of linear regression analysis on log10 ACTB (sample Thal-QC-005) not significantly different from zero at the 95% confidence level (p > 0.05), confirming the amplification stability of QC material in the monitoring conditions (Fig. 2C). Agarose gel electrophoresis revealed clear, sharp DNA bands (from sample Thal-QC-005) with no obvious degradation under all conditions (Fig. 2D). The gap-PCR (sample Thal-QC-001 and -002) and Sanger sequencing (sample Thal-QC-005, −006, −008 and − 010) results indicated that repeated freeze-thaw cycles up to five times did not affect the detection results of various reference mutation sites (Fig. 2E-G). These findings confirm that the cell line-derived QC materials exhibit excellent stability under various storage and handling conditions. QC materials commutability The thalassemia QC materials were systematically characterized using several genotyping methods, and all detection results were summarized in Table 2. Specifically, Fig. 3 presents the characterization of four α-thalassemia QC materials: three deletion types (−−SEA/αα, −α3.7/αα, and -α4.2/αα) were detected by fluorescence-based PCR melting curve analysis (Fig. 3A), Gap-PCR (Fig. 3C), PCR-flow hybridization (Fig. 3E), and TOF-MS (Fig. 3F); one point mutation type (αWSα/αα) was detected using fluorescence-based PCR melting curve analysis (Fig. 3B), PCR-reverse dot blot hybridization (Fig. 3D), PCR-flow hybridization (Fig. 3E), and TOF-MS (Fig. 3F). Similarly, Fig. 4 shows the characterization of four representative β-thalassemia QC materials (βCD41–42(-TTCT)/βN, βIVS-II-654(C > T)/βN, βIVS-I-1(G > T)/βN, βCD17(A > T)/βN) via fluorescence-based PCR melting curve analysis (Fig. 4A), PCR-reverse dot blot hybridization (Fig. 4B), PCR-flow hybridization (Fig. 4C), and TOF-MS (Fig. 4D). The data demonstrate high consistency across different methods within the 12 patient-derived cell lines examined, which aligns with the principle of analytical reproducibility and commutability emphasized in methodological studies. No failed cases or unexpected results were observed across any of the methods. These results suggest that the 12 cell lines-based QC material panel is suitable for internal quality control in thalassemia genetic testing. Table 2Genetic testing results of QC materials.SamplesGenotypesSanger sequencingFluorescence-based PCR melting curve analysisGap-PCRPCR-reverse dot hybridizationPCR-flow-through hybridizationPCR-MALDI-TOF-MSThal-QC-001Wild type√√√√√√Thal-QC-002--SEA/ααOut of detection range√√Out of detection range√√Thal-QC-003-α3.7/ααOut of detection range√√Out of detection range√√Thal-QC-004-α4.2/ααOut of detection range√√Out of detection range√√Thal-QC-005αWSα/αα√√Out of detection range√√√Thal-QC-006βCD41–42(-TTCT)/βN√√Out of detection range√√√Thal-QC-007βCD43(G > T)/βN√√Out of detection range√√√Thal-QC-008βIVS-II-654(C > T)/βN√√Out of detection range√√√Thal-QC-009βIVS-I-1(G > T)/βN√√Out of detection range√√√Thal-QC-010βCD17(A > T)/βN√√Out of detection range√√√Thal-QC-011βCD-28(A > G)/βN√√Out of detection range√√√Thal-QC-012βCAP+40–43(-AAAC)/βN√√Out of detection range√√√Thal-QC-013βE(79G > A)/βN√√Out of detection range√√√Note: The “√” indicates that the genotype detected by this method is in accordance with the expected result. Genetic testing results of QC materials. Note: The “√” indicates that the genotype detected by this method is in accordance with the expected result. Commutability test of α-thalassemia cell QC materials. (A) Detection of deletional α-thalassemia mutations using fluorescence-based PCR melting curve analysis. Upper panel: characteristic melting peaks for the reference gene (blue) and the -α3.7 deletion (orange). Lower panel: characteristic melting peaks for the – −SEA deletion (blue) and the -α4.2 deletion (orange). (B) Detection of non-deletional α-thalassemia mutations using fluorescence-based PCR melting curve analysis. The graph shows the melting curves for the αWS (blue), αCS (green), and reference gene (orange). (C) Detection of deletional α-thalassemia mutations using Gap-PCR method. (D) Detection of α-thalassemia mutations using PCR-reverse dot hybridization method. The dashed cycle labels the variant dots with positive coloration (red) and the corresponding wild-type dots (blue). The right side shows a schematic of dots distribution: N, normal control or wild-type; M, mutant. (E) Detection of α-thalassemia mutations using PCR-flow-through hybridization method. The dashed cycle labels the variant dots with positive coloration (red) and the corresponding wild-type dots (blue). The right side shows a schematic of dots distribution: Bio, biotin control; N, normal control or wild-type; M, mutant. (F) Detection of α-thalassemia mutations using PCR-MALDI-TOF-MS. Characteristic peaks of different variants and their wild-type counterparts are labeled (the wild-type peaks for sample Thal-QC-003 and -004 are not shown in the field of view). The table provides peak heights and height ratios (mutant-to-wild-type) for each genotype, indicating which peak corresponds to which mutation. Commutability test of β-thalassemia cell QC materials. (A) Identification of β-thalassemia by fluorescence PCR melting curve method. Arrows indicate the wild-type peaks (N) or mutant peaks (M) of the corresponding gene sites. (B) Identification of β-thalassemia by PCR-reverse dot hybridization method. The dashed cycle labels the variant dots with positive coloration (red) and the corresponding wild-type dots (blue). The lower part shows a schematic of dots distribution: N, normal control or wild-type; M, mutant. (C) Identification of β-thalassemia by PCR-flow-through hybridization method. The dashed cycle labels the variant dots with positive coloration (red) and the corresponding wild-type dots (blue). The right side shows a schematic of dots distribution: Bio, biotin control; N, normal control or wild-type; M, mutant. (D) Identification of β-thalassemia by PCR-MALDI-TOF-MS. Characteristic peaks of different mutant (M) and their wild-type (N) counterparts are labeled. The table provides peak heights and height ratios (mutant-to-wild-type) for each genotype, indicating which peak corresponds to which mutation. Discussion This study developed a group Immortalized B-Lymphoblastoid cell lines as a QC material for thalassemia genetic testing. By optimizing key parameters, including initial cell density, cytokine supplementation timing and post-infection culture conditions, we substantially improved the Epstein-Barr virus (EBV) transformation method, achieving a success rate approximately 90% in establishing stable cell lines. In addition, these immortalized cell lines exhibit robust stability during continuous culture, maintaining rapid proliferation and stable cell morphology over multiple passages. This addresses the efficiency and consistency limitations of conventional approaches. We comprehensively evaluated the feasibility of using these immortalized cell lines as QC materials. The prepared QC material, using serum-free freezing medium, effectively prevents exogenous nucleic acid contamination and demonstrates excellent stability [18]. The DNA fragment integrity, ACTB copy numbers and reference mutant loci of within the QC material also retained excellent stability after repeated freeze-thaw cycles, long-term storage, and short-term storage at room temperature. Furthermore, the QC material shows strong commutability, as consistent genotyping results were obtained across multiple thalassemia genetic testing platforms. Compared to conventional QC materials based on limited clinical samples or synthetic DNA, our immortalized cell line-based alternative provides a renewable source of intact genomic DNA within an authentic cellular matrix, closely mimicking patient samples [15], [21], [22]. This allows end-to-end process monitoring, including nucleic extraction, and is produced through a standardized, efficient workflow ensuring consistent quality. This platform technology, which creates immortalized cell lines from individuals with specific genetic variants, also enables the development of standardized QC materials for a range of monogenic disorders, and supports their use in various application scenarios such as external quality assessment and novel assay validation [23], [24], [25]. It should be noted that the present findings are based on 12 patient-derived cell lines. While the consistency across methods was high within this set, the results may not be fully generalizable to all possible thalassemia genotypes or testing conditions. Future studies with larger and more diverse sample cohorts are warranted to further validate the commutability of these QC materials. In conclusion, we have developed and validated a novel, renewable, cell-based QC material for thalassemia detection. The optimized EBV immortalization protocol ensures high efficiency and reliability, while the cellular nature of the material provides a superior alternative to existing options. With established strategies to address its limitations and a clear path for expansion, this platform holds significant potential to enhance quality control standards not only for thalassemia testing but also for the broader field of molecular genetic diagnostics. Authors contribution Huiling Zhang: Writing – original draft, Data curation, Formal analysis. Liqiao Han: Resources, Methodology. Yingyi Feng, Longqiang Yang, Yuxiang Qiu, Cheng Zhang, Tingting Li, Qi Kong, Yuanyuan Liu and Chenyang Yao: Validation. Peifeng Ke: Funding acquisition. Xianzhang Huang: Supervision. Yi Wang: Conceptualization, Funding acquisition and Project administration. Authors statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. CRediT authorship contribution statement Huiling Zhang: Writing – original draft, Formal analysis, Data curation. Liqiao Han: Resources, Methodology. Yingyi Feng: Validation. Longqiang Yang: Validation. Yuxiang Qiu: Validation. Cheng Zhang: Validation. Tingting Li: Validation. Peifeng Ke: Funding acquisition. Qi Kong: Validation. Yuanyuan Liu: Validation. Chenyang Yao: Validation. Xianzhang Huang: Supervision. Yi Wang: Project administration, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare no conflicts of interest. Acknowledgements This work was financially supported by the Guangdong Basic and Applied Basic Research Foundation [2021A1515220163], Guangzhou Municipal Science and Technology Project [2025A03J0466], Science Foundation of Guangdong Provincial Hospital of Chinese Medicine [YN2023MS45], Guangdong Provincial Clinical Research Center for Laboratory Medicine [2023B110008], and Guangdong Provincial Hospital of Chinese Medicine Achievement Transformation and Incubation Project [ZH2025QT05]. Contributor Information Xianzhang Huang, Email: huangxz020@163.com. Yi Wang, Email: wangyi2719@126.com. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.